Advertisement

Paediatric Tumours

  • Lucy Fowkes
  • Sue ChuaEmail author
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Radiotherapy (RT) is employed as a curative rather than palliative treatment in children with cancer. Paediatric cancers are rare, so use of positron emission tomography-computed tomography (PET-CT) to plan RT is typically performed by specialist centres. A physiologically heterogeneous population, ranging from neonate to adolescent, has practical implications for image acquisition, interpretation and RT dose. Increased susceptibility to the effects of ionising radiation leads to pronounced adverse effects, with the long-term risk of secondary malignancy amplified by concurrent chemotherapy and imaging studies performed during and after treatment [1].

Keywords

Concurrent Chemotherapy Paediatric Cancer Secondary Malignancy Reduce Radiation Dose Procedural Compliance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Meadows AT, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol. 2004;34(3):214–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Birk Christensen CB, Loft L, Kiil Berthelsen A. PET/CT radiotherapy planning in children. In: Kinggaard MH, Federspiel P, editors. PET/CT radiotherapy planning part 3: a technologist guide. Vienna: European Association of Nuclear Medicine; 2012. p. 67–71.Google Scholar
  4. 4.
    Maraldo MV, et al. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61(4):717–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Colavolpe C, et al. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51(6):828–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Lu MY, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54(1):42–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Gains JE, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52(7):1041–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Seo Y, et al. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012;14(6):735–42.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ricard F, et al. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med. 2011;36(8):672–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Spehl TS, Gotz IS. PET/CT-based radiotherapy planning in brain malignancies. In: E.A.f.N. Medicine, editor. PET/CT radiotherapy planning part 3: a technologist guide. Vienna: European Association of Nuclear Medicine; 2012.Google Scholar
  11. 11.
    Rakheja R, et al. Intravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET/CT. Am J Nucl Med Mol Imaging. 2011;1(1):29–35.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Gelfand MJ, et al. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol. 2005;35(10):984–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Garcia C, et al. Effective reduction of brown fat FDG uptake by controlling environmental temperature prior to PET scan: an expanded case series. Mol Imaging Biol. 2010;12(6):652–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Radiology & Radionuclide RadiologyThe Royal Marsden NHS Foundation TrustLondonUK
  2. 2.Department of Nuclear Medicine and PETRoyal Marsden NHS Foundation TrustSuttonUK

Personalised recommendations